Loading clinical trials...
Loading clinical trials...
Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback
Conditions
Interventions
Defibrotide
Locations
4
United States
University of California Los Angeles
Los Angeles, California, United States
University of Florida
Gainesville, Florida, United States
New York Medical College
Valhalla, New York, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Start Date
July 1, 2017
Primary Completion Date
December 1, 2026
Completion Date
December 1, 2027
Last Updated
May 23, 2025
NCT05170412
NCT06526117
NCT06665997
NCT07431398
NCT07222475
NCT05377372
Lead Sponsor
New York Medical College
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions